In this podcast, Cancer.Net Associate Editors discuss new research from the ASCO20 Virtual Scientific Program and what it means for patients.

Dr. Gevorg Tamamyan describes what cancer care is like for children in Armenia and the role charities play in helping with the costs of diagnosis and treatment.

Read research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on immunotherapy for metastatic colorectal cancer and gestational trophoblastic disease, maintenance therapy for advanced bladder cancer, the potential of precision medicine for childhood cancers, and targeted therapy after surgery for EGFR-positive non-small cell lung cancer.

Lea los puntos destacados de la investigación del programa científico virtual ASCO20 que se acaban de publicar. Incluyen estudios sobre inmunoterapia para el cáncer colorrectal metastásico y la enfermedad trofoblástica gestacional, terapia de mantenimiento para el cáncer de vejiga avanzado, el potencial de la medicina de precisión para el cáncer infantil y la terapia dirigida después de la cirugía por EGFR (receptor del factor de crecimiento epidérmico), positivo de cáncer de pulmón de células no pequeñas.

Read research highlights that will be presented at the 2019 ASCO Annual Meeting, covering low-fat diets and risk of breast cancer death, chemotherapy for older adults with esophageal cancer, targeted therapy for those at risk for multiple myeloma, the rate of genetic changes in childhood cancers, and a new targeted therapy for childhood central nervous system tumors.

The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?

A cancer diagnosis can affect your ability to have a child in the future. Start thinking about your fertility before treatment starts and how to plan for life after treatment.

Advocate Angela Lee shares her advocacy story and 3 things to consider if you’re a long-term survivor.